Continuation of R&D investment
First written in FY2017-Q1. 23 of 35 entries say "Advanced", first in FY2017. Latest entry: 2026-11-09.
1 other company's latest entry also says "Softened".
- FY2026AdvancedAnnual report
「Research and development expenses were ¥20,585 million, up 9.9% year on year.」
R&D expenses were ¥20,585 million, up 9.9% year on year. The annual results reflected an expansion in R&D investment, including investment associated with licensing and joint development for NM81, エクテリー, gMSC1 and ナベニバルト, among others. - 2026-05-30AdvancedGeneral Meeting of Shareholders
「当連結会計年度の研究開発費につきましては、20,585百万円(対前年同期比9.9％増)となりました。」
研究開発費の増加継続と、複数のライセンス・共同開発契約に伴う投資が記載された。 - FY2026-H1AdvancedAnnual report
「Research and development expenses were ¥11,672 million, up 95.4% from the previous interim consolidated accounting period.」
Research and development expenses were ¥11,672 million, up 95.4% from the previous interim period. Payments of upfront fees under new license agreements and other items were also explained as factors behind the increase in research and development expenses. - FY2025-H1AdvancedAnnual report
「Research and development expenses were ¥5,973 million, up 4.1% from the previous interim consolidated accounting period.」
Research and development expenses were ¥5,973 million, up 4.1% from the interim consolidated accounting period of the previous year. Continued and increased research and development investment under the long-term management plan was demonstrated by the figures. - FY2024-Q3AdvancedAnnual report
「The primary factor behind the increase in selling, general and administrative expenses was that, as a result of strategic investment, research and development expenses increased 34.7% year on year to ¥8,502 million.」
As a result of strategic investment, research and development expenses for the cumulative third-quarter period increased 34.7% year on year to ¥8,502 million, indicating continued growth in research and development investment. - FY2024-Q2AdvancedAnnual report
「The primary factor behind the increase in selling, general and administrative expenses was that, as a result of strategic investment, research and development expenses increased 32.5% year on year to ¥5,738 million.」
As a result of strategic investment under the long-term management plan, research and development expenses increased 32.5% year on year to ¥5,738 million. - FY2024-Q1AdvancedAnnual report
「The primary factor behind the increase in selling, general and administrative expenses was that research and development expenses increased 28.1% year on year to ¥2,600 million.」
Research and development expenses were ¥2,600 million, up 28.1% year on year. The increase in research and development investment was specifically identified as a factor behind the rise in selling, general and administrative expenses during the quarter. - FY2023-Q3AdvancedAnnual report
「The primary factor behind the increase in selling, general and administrative expenses was that research and development expenses increased 4.6% year on year to ¥6,310 million.」
Research and development expenses increased 4.6% year on year to ¥6,310 million, with the increase in research and development investment demonstrated by specific figures. - FY2023-Q2AdvancedAnnual report
「The primary factor behind the increase in selling, general and administrative expenses was that research and development expenses increased 8.0% year on year to ¥4,330 million.」
Research and development expenses increased 8.0% year on year to ¥4,330 million, and the increase in research and development investment was identified as a factor behind the rise in selling, general and administrative expenses. - FY2023-Q1AdvancedAnnual report
「The primary factor behind the increase in selling, general and administrative expenses was that research and development expenses increased 8.8% year on year to ¥2,030 million.」
Research and development expenses for the first quarter were ¥2,030 million, up 8.8% year on year. Continued and increased research and development investment was demonstrated by specific figures. - FY2022AdvancedAnnual report
「The primary factor behind the increase in selling, general and administrative expenses was that research and development expenses increased 25.0% year on year to ¥8,420 million.」
Research and development expenses increased 25.0% from ¥6,736 million in the previous fiscal year to ¥8,420 million, with expanded research and development investment reflected in the full-year results. - FY2022-Q3AdvancedAnnual report
「The primary factor behind the increase in selling, general and administrative expenses was that research and development expenses increased 24.1% year on year to ¥6,035 million.」
Research and development expenses for the cumulative third-quarter period were ¥6,035 million, up 24.1% year on year. They also increased from ¥4,008 million in the cumulative second-quarter period of the previous year, indicating continued expansion of research and development investment. - FY2022-Q2AdvancedAnnual report
「The primary factor behind the increase in selling, general and administrative expenses was that research and development expenses increased 22.7% year on year to ¥4,008 million.」
Research and development expenses increased 22.7% year on year to ¥4,008 million, confirming continued growth in research and development investment during the cumulative second-quarter period. - FY2022-Q1AdvancedAnnual report
「The primary factor behind the increase in selling, general and administrative expenses was that research and development expenses increased 18.6% year on year to ¥1,865 million.」
Research and development expenses increased 18.6% year on year to ¥1,865 million, indicating continued research and development investment from the end of the previous fiscal year of ¥6,736 million in the quarterly results. - FY2021AdvancedAnnual report
「Research and development expenses were ¥6,736 million, up 5.0% year on year.」
Research and development expenses were ¥6,736 million, up 5.0% from ¥6,418 million in the previous fiscal year. The increase in research and development investment was reported despite declines in revenue and profit. - FY2021-Q3AdvancedAnnual report
「Research and development expenses were ¥4,862 million, up 2.6% year on year.」
Research and development expenses for the cumulative third-quarter period were ¥4,862 million, up 2.6% from ¥4,741 million in the same period of the previous year. This indicated an increase in spending after year-on-year declines through the previous quarter. - FY2021-Q2RestatedAnnual report
「Total research and development expenses for the cumulative second-quarter consolidated period were ¥3,267 million. There were no material changes in the status of the Group's research and development activities during the cumulative second-quarter consolidated period.」
Research and development expenses were ¥3,267 million, down 2.0% from ¥3,334 million in the same period of the previous year, while the company continued to state that there were no material changes in the status of its research and development activities. - FY2021-Q1RestatedAnnual report
「Total research and development expenses for the cumulative first-quarter consolidated period were ¥1,573 million. There were no material changes in the status of the Group's research and development activities during the cumulative first-quarter consolidated period.」
Research and development expenses were ¥1,573 million, and the company continued to state that there were no material changes in the status of its research and development activities. - FY2020-Q3RestatedAnnual report
「The primary factor behind the decrease in selling, general and administrative expenses was that research and development expenses were ¥4,741 million, down 38.8% year on year.」
Research and development expenses for the cumulative third-quarter period were ¥4,741 million, down 38.8% year on year. The company continued to state that there were no material changes in the status of its research and development activities themselves. - FY2020-Q2RestatedAnnual report
「The primary factor behind the decrease in selling, general and administrative expenses was that research and development expenses were ¥3,334 million, down 41.6% year on year.」
Research and development expenses decreased 41.6% year on year to ¥3,334 million. As in the previous quarter, the reduction in research and development expenses was identified as a factor behind the decrease in selling, general and administrative expenses. - FY2020-Q1SoftenedAnnual report
「The primary factor behind the decrease in selling, general and administrative expenses was that research and development expenses were ¥1,609 million, down 55.0% year on year.」
Research and development expenses decreased 55.0% year on year to ¥1,609 million, indicating a reduction in spending during the quarter after the upward trend through the previous fiscal year. The company stated that there were no material changes in the status of its research and development activities themselves. - FY2019AdvancedAnnual report
「The primary factor behind the increase in selling, general and administrative expenses was that research and development expenses were ¥10,261 million, up 25.9% year on year.」
Research and development expenses increased 25.9% from ¥8,152 million in the previous fiscal year to ¥10,261 million, with increased investment associated with pipeline expansion and progress in research and development reflected in the full-year results. - FY2019-Q3AdvancedAnnual report
「The primary factor behind the increase in selling, general and administrative expenses was that research and development expenses increased 34.0% year on year to ¥7,744 million.」
Research and development expenses for the cumulative third-quarter consolidated period increased 34.0% year on year to ¥7,744 million, and the increase in research and development investment was explicitly identified as a factor behind the rise in selling, general and administrative expenses. - FY2019-Q2AdvancedAnnual report
「The primary factor behind the increase in selling, general and administrative expenses was that research and development expenses increased 56.6% year on year to ¥5,708 million.」
Research and development expenses increased 56.6% year on year to ¥5,708 million, and the increase in research and development investment was explicitly identified as a factor behind the rise in operating expenses. - FY2019-Q1AdvancedAnnual report
「The primary factor was that research and development expenses increased 94.9% from the cumulative first-quarter consolidated period of the previous year to ¥3,579 million.」
Research and development expenses increased 94.9% from ¥1,836 million in the same period of the previous year to ¥3,579 million. Although the company stated that there were no material changes in the status of its research and development activities, the increase in spending was evident. - FY2018AdvancedAnnual report
「This was because research and development expenses increased 26.4% from the previous consolidated fiscal year to ¥8,152 million as the pipeline was expanded and research and development progressed.」
Research and development expenses increased 26.4% from ¥6,450 million in the previous fiscal year to ¥8,152 million, indicating increased investment associated with pipeline expansion and progress in research and development. - FY2018-Q3RestatedAnnual report
「Total research and development expenses for the cumulative third-quarter consolidated period were ¥5,778 million. There were no material changes in the status of the Group's research and development activities during the cumulative third-quarter consolidated period.」
Research and development expenses for the cumulative third-quarter period were ¥5,778 million. The company continued to state that there were no material changes in the status of its research and development activities. - FY2018-Q2RestatedAnnual report
「Total research and development expenses for the cumulative second-quarter consolidated period were ¥3,644 million. There were no material changes in the status of the Group's research and development activities during the cumulative second-quarter consolidated period.」
Research and development expenses for the first half were ¥3,644 million. The company continued to state that there were no material changes in the status of its research and development activities. - FY2018-Q1RestatedAnnual report
「Total research and development expenses for the cumulative first-quarter consolidated period were ¥1,836 million. There were no material changes in the status of the Group's research and development activities during the cumulative first-quarter consolidated period.」
Research and development expenses for the cumulative first-quarter period were ¥1,836 million. The company continued to state that there were no material changes in the status of its research and development activities. - FY2017AdvancedAnnual report
「Group-wide research and development expenses for the consolidated fiscal year were ¥6,450 million.」
Research and development expenses for the full year were ¥6,450 million. Specific progress in research and development activities was also reported, including the launch of Regroth, Phase II trials for KAG-308 and BBI-4000, and consultations with regulators regarding clinical trials for KMW-1. - FY2017-Q3RestatedAnnual report
「Total research and development expenses for the cumulative third-quarter consolidated period were ¥4,985 million. There were no material changes in the status of the Group's research and development activities during the cumulative third-quarter consolidated period.」
Research and development expenses for the cumulative third-quarter period were ¥4,985 million, and the company continued to state that there were no material changes in its research and development activities. - FY2017-Q2RestatedAnnual report
「Total research and development expenses for the cumulative second-quarter consolidated period were ¥3,627 million. There were no material changes in the status of the Group's research and development activities during the cumulative second-quarter consolidated period.」
Research and development expenses for the first half were ¥3,627 million. The company continued to state that there were no material changes in the status of its research and development activities. - FY2017-Q1First statedAnnual report
「Total research and development expenses for the cumulative first-quarter consolidated period were ¥1,899 million. There were no material changes in the status of the Group's research and development activities during the cumulative first-quarter consolidated period.」
Research and development expenses for the quarter were ¥1,899 million, and the company stated that there were no material changes in the status of its research and development activities.